Study of SB-BCLmR-HSPC (BCL11A Enhancer approach) for treatment of transfusion-dependent beta-thalassemia major

Trial Profile

Study of SB-BCLmR-HSPC (BCL11A Enhancer approach) for treatment of transfusion-dependent beta-thalassemia major

Planning
Phase of Trial: Phase I/II

Latest Information Update: 02 Oct 2017

At a glance

  • Drugs SB-BCLmR-HSPC (Primary)
  • Indications Beta-thalassaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Sangamo Therapeutics
  • Most Recent Events

    • 02 Oct 2017 According to a Sangamo Therapeutics media release, this trial is expected to begin in the first half of 2018.
    • 02 Oct 2017 Planned initiation date changed from 1 Jan 2016 to 1 Jan 2018, according to a Sangamo Therapeutics media release.
    • 02 Oct 2017 According to a Sangamo Therapeutics media release, the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top